The at-home testing industry, from Covid to cancer, may be worth over $2 billion by 2025 : Rashtra News #athome #testing #industry #Covid #cancer #worth #billion The at-home testing market is bigger than just Covid tests, and it's bigger than over-the-counter pregnancy tests.In fact, the emerging marketplace of consumer-initiated lab testing may be worth more
Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday.
Inhibrx Inc. and Sanofi SA have agreed to a deal worth up to $2.2 billion, whereby the latter’s Aventis Inc. subsidiary will acquire INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation therapy undergoing a registrational trial for AAT deficiency (AATD), an inherited genetic disorder caused by single nucleotide variants in the SERPINA1 gene.